Dashboard
Manage Tickers

SLDB


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

solid-biosciences-sgt-003-gene-therapy-for-duchenne-muscular-dystrophy-granted-innovation-passport-under-new-innovative-licensing-and-access-pathway
Solid Biosciences' SGT-003 Gene Therapy Fo...
11/06/2025 13:27:59

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision ...

citigroup-maintains-buy-on-solid-biosciences-lowers-price-target-to-14
Citigroup Maintains Buy on Solid Bioscienc...
11/05/2025 20:42:39

Citigroup analyst Yigal Nochomovitz maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and lowers the price target from $1...

jp-morgan-maintains-overweight-on-solid-biosciences-lowers-price-target-to-11
JP Morgan Maintains Overweight on Solid Bi...
11/05/2025 20:16:56

JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 17:06:03

barclays-maintains-overweight-on-solid-biosciences-lowers-price-target-to-9
Barclays Maintains Overweight on Solid Bio...
11/04/2025 14:01:43

Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $10 ...

chardan-capital-maintains-buy-on-solid-biosciences-maintains-15-price-target
Chardan Capital Maintains Buy on Solid Bio...
11/04/2025 13:31:10

Chardan Capital analyst Geulah Livshits maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $15 price target.

solid-biosciences-reports-interim-data-from-inspire-duchenne-trial-showing-strong-microdystrophin-expression-and-muscle-biomarker-improvements
Solid Biosciences Reports Interim Data Fro...
11/03/2025 21:26:30

INSPIRE DUCHENNE – Interim Clinical Data UpdateINSPIRE DUCHENNE is a Phase 1/2 first-in-human, open-label, single-dose, multice...

solid-biosciences-q3-eps-048-misses-043-estimate
Solid Biosciences Q3 EPS $(0.48) Misses $(...
11/03/2025 21:23:41

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $...

solid-biosciences-announces-non-exclusive-licensing-agreement--with-kinea-bio-granting-kinea-license-to-utilize-aav-slb101-as-the-delivery-backbone-for-kna-155
Solid Biosciences Announces Non-Exclusive ...
09/23/2025 12:10:16

chardan-capital-maintains-buy-on-solid-biosciences-maintains-15-price-target
Chardan Capital Maintains Buy on Solid Bio...
08/14/2025 16:18:47

Chardan Capital analyst Geulah Livshits maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $15 price target.

jp-morgan-maintains-overweight-on-solid-biosciences-lowers-price-target-to-13
JP Morgan Maintains Overweight on Solid Bi...
08/14/2025 15:49:17

JP Morgan analyst Anupam Rama maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and lowers the price target from $...

wedbush-maintains-outperform-on-solid-biosciences-lowers-price-target-to-14
Wedbush Maintains Outperform on Solid Bios...
08/13/2025 14:44:08

Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lowers the price target from $17...

solid-biosciences-q2-eps-042-beats-053-estimate
Solid Biosciences Q2 EPS $(0.42) Beats $(0...
08/12/2025 20:36:14

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0...

solid-biosciences-receives-fda-fast-track-designation-for-sgt-501-gene-therapy-for-catecholaminergic-polymorphic-ventricular-tachycardia
Solid Biosciences Receives FDA Fast Track ...
07/23/2025 12:01:54

solid-biosciences-receives-fda-ind-and-health-canada-cta-approval-for-first-in-class-cardiac-gene-therapy-to-treat-catecholaminergic-polymorphic-ventricular-tachycardia
Solid Biosciences Receives FDA IND And Hea...
07/08/2025 20:08:11

- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -- SGT-...

citigroup-initiates-coverage-on-solid-biosciences-with-buy-rating-announces-price-target-of-14
Citigroup Initiates Coverage On Solid Bios...
06/26/2025 11:50:54

Citigroup analyst Yigal Nochomovitz initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Pr...

analyst-downgrades-sarepta-as-elevidys-safety-clouds-future-demand
Analyst Downgrades Sarepta As Elevidys Saf...
06/20/2025 18:10:20

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenu...

hc-wainwright--co-reiterates-buy-on-solid-biosciences-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Soli...
06/17/2025 11:09:54

HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $20 price target.

sarepta-therapeutics-kulr-technology-group-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Sarepta Therapeutics, KULR Technology Grou...
06/16/2025 12:38:15

why-incyte-shares-are-trading-higher-by-around-10-here-are-20-stocks-moving-premarket
Why Incyte Shares Are Trading Higher By Ar...
06/16/2025 10:00:21

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION